EDIT
Editas Medicine, Inc.Healthcare · $396M market cap
Verdict
We can't put a fair value on EDIT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow EDIT
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 3, 2026: no open-market purchases, 3 sales worth $19K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Sales
O'Neill Gilmore Neil
CEO · 2026-09-03
Sold
$16K
Parison Amy
SVP, Chief Financial Officer · 2026-09-03
Sold
$1K
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER · 2026-09-03
Sold
$2K
Other filings
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works